Windtree Therapeutics and Eleison Pharmaceuticals have announced results from a study that demonstrated the feasibility of delivering Eleison’s inhaled lipid cisplatin (ILC) via Windtree’s Aerosol Delivery System (ADS). In March 2018, the companies announced that they had partnered for development of ILC for the treatment of lung cancer.
According to the companies, the study showed that the ADS technology aerosolized the same volume of ILC much faster than conventional nebulizer technology, 20 minutes for the ADS compared to 2 hours for the conventional nebulizer used in a Phase 2 trial evaluating ILC for the treatment of osteosarcoma lung metastases. In addition, the aerosol characteristics were comparable for the ADS and the conventional nebulizer, and the cytotoxicity of the ILC was unaffected by the ADS.
Eleison CEO Edwin Thomas commented, “Combining faster delivery time with our aerosolized ILC and using less volume and having less waste would have the potential to enhance the usability and acceptance of ILC. We are very excited about the prospects of this innovative combination to further differentiate our program and look forward to continued opportunities for collaboration between Eleison and Windtree.”
Windtree Therapeutics CEO Craig Fraser said, “We are very encouraged by this research collaboration to date, which has demonstrated the drug delivery potential of our device technology beyond treating premature infants with RDS. The ADS is an innovative platform that we plan to continue to study in our Aerosurf development program and potentially in additional acute care drug delivery uses, starting with this important area of oncology and Eleison’s unique product candidate ILC.”
Read the Windtree Therapeutics and Eleison Pharmaceuticals press release.
